-+ 0.00%
-+ 0.00%
-+ 0.00%

NOVO'S CAGRISEMA WAS ASSOCIATED WITH 25% MEAN WEIGHT LOSS AMONG EARLY RESPONDERS IN A POST HOC ANALYSIS OF REDEFINE 1 PRESENTED AT OBESITYWEEK® 2026

Reuters·11/15/2026 13:01:33

Please log in to view news